Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 8.01 (Other Events). Pilot study underway for ET-700, Eton’s extended-release zinc acetate formulation.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Pilot study underway for ET-700, Eton’s extended-release zinc acetate formulation
- Trial compares ET-700 against Galzin® and placebo in Wilson disease
- Clinical progress creates potential pipeline value, but efficacy and approval remain unproven
- Press release dated April 27, 2026 provides additional study details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.